Core Viewpoint - Jianmin Group reported a net profit of 221 million yuan for H1 2025, representing a year-on-year decline of 7.83% while experiencing rapid growth in industrial revenue and expected volume increase in pediatric new drugs [1] Group 1: Financial Performance - The net profit for H1 2025 was 221 million yuan, down 7.83% year-on-year [1] - R&D expenses reached 52.97 million yuan in H1 2025, an increase of 30.89% year-on-year [1] Group 2: Business Strategy - The company adheres to a dual-brand strategy with "Longmu" for pediatric drugs and "Jianmin" for chronic disease and family essential medications, focusing on multiple core products [1] - The OTC product line is expected to maintain rapid revenue growth due to brand strategy upgrades and accelerated product launches [1] Group 3: Product Development - The company is enhancing its product portfolio in the digestive field, with two products, Tongjiao Granules and Zhizhu Tongbian Granules, entering Phase III clinical trials [1] - The company is recognized as a leading pediatric drug enterprise in China, with a clear release schedule for innovative Chinese medicine products in hospitals [1]